Shire Receives Approvable Letter From FDA for Intuniv Extended
Release, a Nonstimulant for ADHD
Shire plc announced today that it has received an approvable letter
from the FDAn for Intuniv extended release tablets , a nonstimulant
selective alpha-2A-receptor agonist, which has been studied in
children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
Powered by LSoft's LISTSERV(R) list management software